Teva Pharma (NYSE: TEVA) reported Q4 EPS of $1.28, $0.01 worse than the analyst estimate of $1.29. Revenue for the quarter came in at $4.88 billion versus the consensus estimate of $4.83 billion.

Non-GAAP EPS adjusted to exclude Dec 15 equity offerings was $1.32.

GUIDANCE:

Teva Pharma sees Q1 2016 EPS of $1.32-$1.36, versus the consensus of $1.21. Teva Pharma sees Q1 2016 revenue of $4.7-4.9 billion, versus the consensus of $4.92 billion.

"2015 was a year of exceptional strategic, operational and financial performance for Teva", stated Erez Vigodman, President and CEO of Teva.

"Our strong focus on solidifying the foundation of Teva and improving the fundamentals of our business is manifesting itself in the consistent improvement of our operating and financial results.

Once the company was put on solid footing, we took the offensive and through a series of compelling acquisitions, partnerships and bold strategic moves, we are transforming Teva.

We are building a new company with a solid foundation, significantly enhanced financial profile, excellent generic business, promising specialty franchises and pipeline and diversified net revenues and profit streams. We are positioned to offer top line and bottom line growth and to continue the transformation of our business model, serving hundreds of millions of patients in the world on a daily basis and unlocking significant value for our shareholders."

Vigodman continued, "In 2016, our main focus will be closing and integrating the Actavis Generics, Rimsa and Takeda BV deals, fully capturing first year synergies, and continuing to deliver on the promise in our specialty pipeline through launches, submissions and other important clinical milestones, in conjunction with potential measures we will take to further augment our core therapeutic areas.

Teva is well positioned to become a pharmaceutical company that can truly make a difference in our world."

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.